Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

December 21, 2025

Study Completion Date

June 30, 2026

Conditions
Leptomeningeal Metastasis
Interventions
DRUG

186RNL

"All participants will be required to have an Ommaya Reservoir and a CSF Flow Study.~Participants will receive a single 5cc dose of 186RNL via Ommaya Reservoir."

Trial Locations (6)

10075

Lenox Hill Hospital, New York

11030

Northshore University Hospital, Manhasset

43201

Ohio State University Hospital, Columbus

60611

Northwestern Memorial Hospital Olson Pavilion, Chicago

75390

Universiy of Texas Southwestern Medical Center, Dallas

78229

UT Health Science Center San Antonio / Mays Cancer Center, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Plus Therapeutics

INDUSTRY